{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BTCY","limit":50},"count":50,"signals":[{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":25,"context":"rapid technological change. | | |  |  |  We face competition from other medical device companies that focus on similar markets. | | |  |  |  Unsuccessful clinical trials of our products could have a material adverse effect on our prospects. | | |  |  |  Intellectual property litigation and infringement claims could cause us to incur significant expenses. | | |  |  |  If we are unable to protect the confidentiality of o","filed_date":"2025-12-19","accession":"0001493152-25-028614","full_text":"https://origin.rootz.global/static/filing/0001493152-25-028614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":43,"context":"cantly increase our operating costs. | 21 | | **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2025-07-18","accession":"0001641172-25-020105","full_text":"https://origin.rootz.global/static/filing/0001641172-25-020105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":43,"context":"cantly increase our operating costs. | 21 | | **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2025-07-15","accession":"0001641172-25-019755","full_text":"https://origin.rootz.global/static/filing/0001641172-25-019755.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":41,"context":"d significantly increase our operating costs. **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2024-06-27","accession":"0001493152-24-025344","full_text":"https://origin.rootz.global/static/filing/0001493152-24-025344.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder. 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to each of the Buyers that, as of the date her","filed_date":"2024-06-24","accession":"0001493152-24-024888","full_text":"https://origin.rootz.global/static/filing/0001493152-24-024888.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder. 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to each of the Buyers that, as of the date her","filed_date":"2024-03-26","accession":"0001493152-24-011344","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011344.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":30,"context":"such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder. | 4 | | ** ** 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to each of the Buyers that, as o","filed_date":"2023-09-20","accession":"0001493152-23-033139","full_text":"https://origin.rootz.global/static/filing/0001493152-23-033139.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"d significantly increase our operating costs. **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2023-06-29","accession":"0001493152-23-022974","full_text":"https://origin.rootz.global/static/filing/0001493152-23-022974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":16,"context":"promulgated under the Securities Act, without giving effect to Nasdaqs 20% Rule (the Nasdaq Proposal); | | |  5. |  To approve, on a non-binding advisory basis, the compensation paid to the Companys named executive officers (the Say-on-Pay Proposal); | | |  6. |  To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to the Companys named executive officers (the S","filed_date":"2023-03-13","accession":"0001493152-23-007414","full_text":"https://origin.rootz.global/static/filing/0001493152-23-007414.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"d significantly increase our operating costs. **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2022-07-14","accession":"0001493152-22-019256","full_text":"https://origin.rootz.global/static/filing/0001493152-22-019256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":23,"context":"to such term in Section 3(v). Issuer Free Writing Prospectus shall mean an issuer free writing prospectus, as defined in Rule 433. Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(t). Net Proceeds shall have the meaning ascribed to such term","filed_date":"2022-03-22","accession":"0001493152-22-007463","full_text":"https://origin.rootz.global/static/filing/0001493152-22-007463.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":48,"context":"30 | | |  |  5.1 |  Organization |  30 | | |  |  5.2 |  Authorization; No Conflict |  30 | | |  |  5.3 |  Validity; Binding Nature |  31 | | |  |  5.4 |  Financial Condition |  31 | | |  |  5.5 |  No Material Adverse Effect |  31 | | | | | |  |  5.6 |  Litigation |  31 | | |  |  5.7 |  Ownership of Properties; Liens |  32 | | |  |  5.8 |  Capitalization |  32 | | |  |  5.9 |  Pension Plans |  32 | | |  |  5.10 |  Invest","filed_date":"2021-12-28","accession":"0001493152-21-032595","full_text":"https://origin.rootz.global/static/filing/0001493152-21-032595.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"d significantly increase our operating costs. **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2021-06-22","accession":"0001493152-21-014912","full_text":"https://origin.rootz.global/static/filing/0001493152-21-014912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"oring industry, which could significantly increase our operating costs. **If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2020-07-15","accession":"0001493152-20-013313","full_text":"https://origin.rootz.global/static/filing/0001493152-20-013313.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ime ascribed to such term in Section 3.1(o). Lien means a lien, charge, pledge, security interest, hypothecation, mortgage, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Person means an individual or corporation, partnership","filed_date":"2019-12-20","accession":"0001493152-19-019557","full_text":"https://origin.rootz.global/static/filing/0001493152-19-019557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"oring industry, which could significantly increase our operating costs. **If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2019-07-16","accession":"0001493152-19-010700","full_text":"https://origin.rootz.global/static/filing/0001493152-19-010700.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"oring industry, which could significantly increase our operating costs. **If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2018-07-13","accession":"0001511164-18-000427","full_text":"https://origin.rootz.global/static/filing/0001511164-18-000427.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ompany with the SEC pursuant to Rule 424(b)(5) under the Securities Act and in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference. (ee) Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2018-06-28","accession":"0001511164-18-000406","full_text":"https://origin.rootz.global/static/filing/0001511164-18-000406.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"oring industry, which could significantly increase our operating costs. **If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2018-03-08","accession":"0001511164-18-000135","full_text":"https://origin.rootz.global/static/filing/0001511164-18-000135.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":21,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $5.50, subject to adju","filed_date":"2017-12-26","accession":"0001511164-17-000781","full_text":"https://origin.rootz.global/static/filing/0001511164-17-000781.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"oring industry, which could significantly increase our operating costs. **If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2017-03-30","accession":"0001511164-17-000138","full_text":"https://origin.rootz.global/static/filing/0001511164-17-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":43,"context":"cantly increase our operating costs. | 19 | | **If our customers are not able to both obtain and maintain adequate levels of third-party reimbursement for services using our products, it would have a material adverse effect on our business.** Healthcare providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental agencies worldwide, private insuranc","filed_date":"2026-07-14","accession":"0001493152-26-033207","full_text":"https://origin.rootz.global/static/filing/0001493152-26-033207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":85,"match_count":10,"context":"Effective as of the closing of the Acquisition Transaction, Kazi Hasan, at that time our sole director and executive officer, resigned as Chief Executive Officer and director and Waqaas Al-Siddiq was appointed the sole director of the Company to fill the vacancy. In addition, our Board of Directors appointed Waqaas Al-Siddiq to serve as our President, Chief Executive Officer and Chairman of the Board of Directors, effective","filed_date":"2018-03-08","accession":"0001511164-18-000135","full_text":"https://origin.rootz.global/static/filing/0001511164-18-000135.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":80,"match_count":10,"context":"Effective as of the closing of the Acquisition Transaction, Kazi Hasan, at that time our sole director and executive officer, resigned as Chief Executive Officer and director and Waqaas Al-Siddiq was appointed the sole director of the Company to fill the vacancy. In addition, our Board of Directors appointed Waqaas Al-Siddiq to serve as our President, Chief Executive Officer and Chairman of the Board of Directors, effective","filed_date":"2017-03-30","accession":"0001511164-17-000138","full_text":"https://origin.rootz.global/static/filing/0001511164-17-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":64,"match_count":3,"context":"uality of our sales force and their ability to penetrate the market and place devices with clinically focused, repeat users of our cardiac study technology. We plan to grow our sales force to address new markets and achieve sales penetration in the markets currently served. Commercial History Full market release of the Bioflux COM device for commercialization launched in April 2019, after receiving its seco","filed_date":"2025-12-19","accession":"0001493152-25-028614","full_text":"https://origin.rootz.global/static/filing/0001493152-25-028614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"t at $300,000. In addition, the Company agreed to grant Mr. Ayanoglou warrants to purchase 200,000 shares of the Companys common stock, during each year of his tenure, granted in equal quarterly installments starting with the first fiscal quarter of employment. The warrants vest monthly on a pro-rata basis over a period of 12 months, with the same 10-year term and the same rights and protections as e","filed_date":"2023-03-13","accession":"0001493152-23-007414","full_text":"https://origin.rootz.global/static/filing/0001493152-23-007414.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":64,"match_count":8,"context":"under, as consideration for the purchase of a business plan along with developmental code and software. Our founder paid approximately $1,000 for the business plan, software and development code. The acquisition was valued at $1,000.  The Company has not generated revenues from its planned principal operations and is considered a development stage company as that term is defined by Financial Accounting Standard Board (FASB)","filed_date":"2015-11-30","accession":"0001078782-15-001957","full_text":"https://origin.rootz.global/static/filing/0001078782-15-001957.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":51,"match_count":2,"context":"nd/or financial resources will be imposed. Failure by the Companys management to manage this expected growth, if it occurs, or unexpected difficulties are encountered during this growth, could have a material adverse impact on the Companys results of operations or financial condition. The Companys ability to operate profitable revenue generating product or service lines (if we are able to establish any product or servic","filed_date":"2015-11-30","accession":"0001078782-15-001957","full_text":"https://origin.rootz.global/static/filing/0001078782-15-001957.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":47,"match_count":4,"context":"assets, or (ii) result in a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under this Agreement. (l) There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investiga","filed_date":"2023-03-13","accession":"0001493152-23-007414","full_text":"https://origin.rootz.global/static/filing/0001493152-23-007414.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":44,"match_count":3,"context":"uality of our sales efforts and our ability to penetrate the market and place devices with clinically focused, repeat users of our cardiac study technology. We plan to grow our sales force to address new markets and achieve sales penetration in the markets currently served. Our principal executive office is located at 203 Redwood Shores Pkwy Suite 600, Redwood City, California, and our telephone number is (","filed_date":"2025-07-18","accession":"0001641172-25-020105","full_text":"https://origin.rootz.global/static/filing/0001641172-25-020105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":44,"match_count":3,"context":"uality of our sales efforts and our ability to penetrate the market and place devices with clinically focused, repeat users of our cardiac study technology. We plan to grow our sales force to address new markets and achieve sales penetration in the markets currently served. Our principal executive office is located at 203 Redwood Shores Pkwy Suite 600, Redwood City, California, and our telephone number is (","filed_date":"2025-07-15","accession":"0001641172-25-019755","full_text":"https://origin.rootz.global/static/filing/0001641172-25-019755.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":44,"match_count":3,"context":"uality of our sales efforts and our ability to penetrate the market and place devices with clinically focused, repeat users of our cardiac study technology. We plan to grow our sales force to address new markets and achieve sales penetration in the markets currently served. We are incorporated in the State of Nevada and our headquarters are in Nevada and Ontario. Our principal executive office is located at","filed_date":"2026-07-14","accession":"0001493152-26-033207","full_text":"https://origin.rootz.global/static/filing/0001493152-26-033207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":42,"match_count":4,"context":"tage within the market by controlling the distribution of all available MCT devices and software solutions. Our primary competitors in the MCT market are: *Biotelemetry (formerly CardioNet), recently acquired by Philips for $2.8B*. We believe that BioTelemetry, Inc. (NASDAQ:BEAT), has the largest network of IDTFs within the MCT market. BioTelemetry is considered a complete solution provider as it produces and distributes","filed_date":"2022-07-14","accession":"0001493152-22-019256","full_text":"https://origin.rootz.global/static/filing/0001493152-22-019256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":42,"match_count":4,"context":"tage within the market by controlling the distribution of all available MCT devices and software solutions. Our primary competitors in the MCT market are: *Biotelemetry (formerly CardioNet), recently acquired by Philips for $2.8B*. We believe that BioTelemetry, Inc. (NASDAQ:BEAT), has the largest network of IDTFs within the MCT market. BioTelemetry is considered a complete solution provider as it produces and distributes","filed_date":"2021-06-22","accession":"0001493152-21-014912","full_text":"https://origin.rootz.global/static/filing/0001493152-21-014912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":41,"match_count":2,"context":"ff against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. *Customer Concentration* ** For the year ended March 31, 2026, two customer accounted for 20% and 10% of the Companys revenues. For the year ended March 31, 2025, one customer accounted for approximately 29% of the Companys revenues. *Fair Value of Financial Instruments* ASC 820 defines fair","filed_date":"2026-07-14","accession":"0001493152-26-033207","full_text":"https://origin.rootz.global/static/filing/0001493152-26-033207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"s data intelligently to explore novel avenues for enhancing healthcare outcomes. Through research and development, we believe we are redefining medical diagnostics and patient care and innovating new AI-driven solutions. As a result of providing our Bioflux and Biotres products, Biotricity has monitored over two billion heartbeats for atrial fibrillation (afib), a leading cause of strokes. Over the past two years,","filed_date":"2025-12-19","accession":"0001493152-25-028614","full_text":"https://origin.rootz.global/static/filing/0001493152-25-028614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":40,"match_count":5,"context":"any or any Subsidiary, which default or event of default has not been cured, if capable of curing, within twenty (20) Business Days, and which default or event of default would or is likely to have a material adverse effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition) or prospects of the Company or any of its Subsidiaries, individuall","filed_date":"2024-04-03","accession":"0001493152-24-012898","full_text":"https://origin.rootz.global/static/filing/0001493152-24-012898.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":40,"match_count":5,"context":"olation or investigation, proceeding or demand letter pending, or to the knowledge of the Company threatened, against the Company, which if adversely determined would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations hereunder or under any other Transaction Document to which the Company is a party. There is no civil, criminal or administrative action, suit,","filed_date":"2021-01-22","accession":"0001493152-21-001637","full_text":"https://origin.rootz.global/static/filing/0001493152-21-001637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"explore novel avenues for enhancing healthcare outcomes. Through cutting-edge research and development, we believe we are redefining medical diagnostics and patient care by developing new innovative AI-driven solutions. We are expanding our AI technology development in remote cardiac care, leveraging proprietary AI technology to provide a suite of predictive monitoring tools to enhance new disease profiling, impro","filed_date":"2026-07-14","accession":"0001493152-26-033207","full_text":"https://origin.rootz.global/static/filing/0001493152-26-033207.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":37,"match_count":4,"context":"t Director of the Board of Adex Mining Inc. (TSX-V:ADE), a Canada-based mining company; and 49 North Resources Inc. (TSXV: FNR), a Saskatchewan focused resource investment company. Dr. Betts was also appointed to the Board of Directors of the Bank of Canada and currently serves as a member of the audit and finance committee and the pension committee. Additionally, Dr. Betts was a member of the New Brunswick Legislative Assembly fr","filed_date":"2018-07-13","accession":"0001511164-18-000427","full_text":"https://origin.rootz.global/static/filing/0001511164-18-000427.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":34,"match_count":3,"context":"uality of our sales force and their ability to penetrate the market and place devices with clinically focused, repeat users of its cardiac study technology. We plan to grow our sales force to address new markets and achieve sales penetration in the markets currently served. Our principal executive office is located at 203 Redwood Shores Pkwy Suite 600, Redwood City, California, and our telephone number is (","filed_date":"2024-06-27","accession":"0001493152-24-025344","full_text":"https://origin.rootz.global/static/filing/0001493152-24-025344.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":33,"match_count":1,"context":"against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. *Customer Concentration* ** During the year ended March 31, 2025, one customer comprised 29% of total account receivables, there was no such concentration risk during the previous year ended March 31,2024. | F-12 | | **BIOTRICITY INC.** **Notes to Consolidated Financial Statements** **Years","filed_date":"2025-07-18","accession":"0001641172-25-020105","full_text":"https://origin.rootz.global/static/filing/0001641172-25-020105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":33,"match_count":1,"context":"against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. *Customer Concentration* ** During the year ended March 31, 2025, one customer comprised 29% of total account receivables, there was no such concentration risk during the previous year ended March 31,2024. | F-12 | | **BIOTRICITY INC.** **Notes to Consolidated Financial Statements** **Years","filed_date":"2025-07-15","accession":"0001641172-25-019755","full_text":"https://origin.rootz.global/static/filing/0001641172-25-019755.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":33,"match_count":1,"context":"force and their ability to penetrate the market and place devices with clinically focused, repeat users of its cardiac study technology. The Company plans to grow its sales force in order to address new markets and achieve sales penetration in the markets currently served. The Company has also developed or is developing several other ancillary technologies, which will require application for further FDA cl","filed_date":"2020-02-14","accession":"0001493152-20-002435","full_text":"https://origin.rootz.global/static/filing/0001493152-20-002435.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":33,"match_count":1,"context":"force and their ability to penetrate the market and place devices with clinically focused, repeat users of its cardiac study technology. The Company plans to grow its sales force in order to address new markets and achieve sales penetration in the markets currently served. Full market release of the Bioflux COM device for commercialization launched in April 2019, after receiving its second and final requir","filed_date":"2026-08-19","accession":"0001493152-26-039209","full_text":"https://origin.rootz.global/static/filing/0001493152-26-039209.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":32,"match_count":4,"context":"assets, or (ii) result in a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under this Agreement. (k) There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investiga","filed_date":"2023-11-06","accession":"0001493152-23-039557","full_text":"https://origin.rootz.global/static/filing/0001493152-23-039557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":32,"match_count":4,"context":"assets, or (ii) result in a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under this Agreement. (l) There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investiga","filed_date":"2023-05-18","accession":"0001493152-23-018125","full_text":"https://origin.rootz.global/static/filing/0001493152-23-018125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":32,"match_count":4,"context":"assets, or (ii) result in a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under this Agreement. (k) There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investiga","filed_date":"2019-07-12","accession":"0001511164-19-000072","full_text":"https://origin.rootz.global/static/filing/0001511164-19-000072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":", require all individuals to have health insurance (with limited exceptions) and impose increased taxes. These factors, in turn, could result in reduced demand for our products and increased downward pricing pressure. Because parts of the 2010 health care law remain subject to implementation, the long-term impact on us is uncertain. The new law or any future legislation could reduce medical procedure volumes, low","filed_date":"2018-03-08","accession":"0001511164-18-000135","full_text":"https://origin.rootz.global/static/filing/0001511164-18-000135.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BTCY","company":"BIOTRICITY INC.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":32,"match_count":4,"context":", require all individuals to have health insurance (with limited exceptions) and impose increased taxes. These factors, in turn, could result in reduced demand for our products and increased downward pricing pressure. Because parts of the 2010 health care law remain subject to implementation, the long-term impact on us is uncertain. The new law or any future legislation could reduce medical procedure volumes, low","filed_date":"2017-03-30","accession":"0001511164-17-000138","full_text":"https://origin.rootz.global/static/filing/0001511164-17-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"b53d32c468aaebab059fc041be40b0c28a83e1425ab19a87a95d9e68fc7c08e7","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"894dbb6b7c4bcf48153a2ccc1ff02b8f09572a2d2f869617b81db012ac0d8ad2","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":81,"hourly_limit":500,"remaining":419,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}